SEPNSepterna, Inc.
Is the business good?
Margins steady. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Margins have held roughly steady, a stable cost structure.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is SEPN?
Septerna, Inc. keeps −44% of every revenue dollar as operating profit, against −82% for the median Biotechnology name.
Operating margin · Biotechnology median −82% · 12 months to Q2 2026
- Share count, year on year
- +2.0%
Share count, year on year · shareholders own a smaller slice than a year ago
| Year | Operating margin |
|---|---|
| FY2023 | 1374% |
| FY2024 | −7518% |
| FY2025 | −149% |
Details›
- Operating margin12 months to Q2 2026
- −44%
- Net margin12 months to Q2 2026
- −25%
- Free cash flow margin
- 106%
- R&D as % of revenue
- 122%
- Revenue, trailing twelve months
- $99M
- Free cash flow, trailing twelve months
- $105M
- Net income, trailing twelve months
- −$24M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Biotechnology
The closest names by size in the same industry